Overview

Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

Status:
Unknown status

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized study, open-label, phase III study.The efficacy of irinotecan and capecitabine combination will be superior to capecitabine alone in term of progression free survival in metastatic breast cancer patients previously treated with anthracycline and taxane.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Center, Korea

Collaborators:

Asan Medical Center
Chung-Ang University
Inha University Hospital
Korea University Anam Hospital
Samsung Medical Center
Seoul National University Bundang Hospital
Seoul National University Hospital
Severance Hospital

Treatments:

Camptothecin
Capecitabine
Irinotecan